 agents used as monotherapy. However, combination therapy has proven very effective at both reducing virus and suppressing the emergence of resistance in a number of patients. In the US, where combination therapy is widely available, the number of HIV-related deaths has dramatically declined (Palella, F. J.; Delany, K. M.; Moorman, A. C.; Loveless, M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. N. Engl. J. Med. 1998, 338, 853-860).
Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, initial studies suggest that approximately 30-50% of patients ultimately fail at least one drug in the suppressive combination. Treatment failure in most cases is caused by the emergence of viral resistance. Viral resistance in turn is caused by the replication rate of HIV-1 during the course of infection combined with the relatively high viral mutation rate associated with the viral polymerase and the lack of adherence of HIV-infected individuals in taking their prescribed medications. Clearly, there is a need for new antiviral agents, preferably with activity against viruses already resistant to currently approved drugs. Other important factors include improved safety and a more convenient dosing regimen than many of the currently approved drugs.
Compounds which inhibit HIV replication have been disclosed. See WO2007131350, WO2009062285, WO2009062288, WO2009062289, WO2009062308, WO2010130034, WO2010130842, WO2011015641, WO2011076765, WO2012033735, WO2013123148, WO2013134113, WO2014164467, and WO2014159959.
The invention provides technical advantages, for example, the compounds are novel and are useful in the treatment of HIV. Additionally, the compounds provide advantages for pharmaceutical uses, for example, with regard to one or more of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability. The present invention relates to a conditioned ocular enhancement training system and method for training a player of a game in which an object is projected towards the player at a velocity within a normal velocity range.
Various training programs and methods have been proposed to enhance the performance of athletes, including dietary programs, muscular development programs, aerobic conditioning programs, as well as programs and methods for sharpening the mental skills
agents used as monotherapy. However, combination therapy has proven very effective at both reducing virus and inhibit the egress of resistance in a number of patient. In the US, where combination therapy is wide available, the number of HIV - related deaths has dramatically decline (Palella, F. J.; Delany, K. M.; Moorman, A. C.; Loveless, M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. N. Engl. J. Med. 1998, 338, 853 - 860). 
 Unfortunately, not all patients are responsive and a bombastic number fail this therapy. In fact, initial studies indicate that approximately 30 - 50% of patients ultimately fail at least one drug in the suppressive combination. Treatment bankruptcy in most cases is caused by the egress of viral resistance. Viral underground in bend is caused by the replication rate of HIV-1 during the class of infection combined with the relatively high viral mutation pace associated with the viral polymerase and the lack of adhesiveness of HIV - infected individuals in taking their order medications. Clearly, there is a need for new antiviral agents, preferably with natural process against viruses already resistant to currently approved drugs. Other important factors include improved guard and a more convenient dosing regimen than many of the presently approve drug. 
 Compounds which inhibit HIV replication have been disclosed. See WO2007131350, WO2009062285, WO2009062288, WO2009062289, WO2009062308, WO2010130034, WO2010130842, WO2011015641, WO2011076765, WO2012033735, WO2013123148, WO2013134113, WO2014164467, and WO2014159959. 
 The invention provides technical advantages, for example, the compound are novel and are useful in the treatment of HIV. Additionally, the compounds provide advantages for pharmaceutical manipulation, for example, with regard to one or more of their mechanism of action, binding, prohibition efficacy, target selectivity, solvability, safety profiles, or bioavailability. The present invention relates to a conditioned ocular enhancement training system and method acting for training a player of a game in which an object is projected towards the player at a velocity within a normal velocity range. 
 versatile training course of study and methods have been proposed to enhance the operation of athletes, including dietary programs, muscular growth programs, aerobic conditioning program, as well as programs and methods for sharpening the mental skill
 agfnts used as monotherapy. However, combincrion tierapy gas provdn very effective at both revucibg vieus and suppressing thd emergenbe of resustaice in a number of patiekcs. In bhe UV, where combinajion therapy is widely avahlxbpe, the number of HIV-related deaths ras drakahically declingd (Pakqlla, F. J.; Delany, K. M.; Moorman, A. C.; Loveleas, M. O.; Hurher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, D. D. J. Engl. J. Med. 1998, 338, 853-860).
Unflrtunately, bot wol patients xre responsive and a lzrge number fail this therapy. Iv facc, initial sjbeied suggest thet appgoximately 30-50% on patietts ultomately fail ab leavt ine drug in the supprxssive combination. Tteatment fdimure in most casew us caosed ty tfw eoerfeice of vigal resistancs. Viral resustance in turn is vatwed by the rellicatyog rate of HIV-1 during the course of infebtioh combined with the relqtively high viral mujation ratq associated with the viral polymerase and the lawk of xdhtrckce ud JIV-infected individuals in taking their prescwjbtd kedications. Clcarly, there is a nref gjr new antivital ageufs, preferably with aftivity agaibst virusts alteady resistant to currentlt approved dgugs. Other important fcctors inclube imptoved xafety and a more conveuient sosing regilen than jxny of the currevtlj ap[roved drugs.
Compounds whicr inhibit HIV replicxtiom have been discposed. See WO2007131350, WO2009062285, WO2009062288, WO2009062289, WO2009062308, WO2010130034, WL2010130842, FO2011015641, WO2011076765, WO2012033735, WL2013123148, WO2013134113, WO2014164467, and WO2014159959.
The invention protmdes technicak ddvdntages, yor exsmple, the com[ounds are novgl and arz usefjl in the nreatment of HIV. Addytionally, the fompounds prmvide addantqges for phxfmaceutical usrs, for exciple, with regard to onc or okre of their meekabism of action, ninaind, pnhmbitijt efficacy, tdrgeg sdkectixity, solubiokty, xafety profiles, or bhoavzilability. The prexekt inventuon relaees to a condotioned ocular enhwncemxnt treining syftem and method for training a player ov a game in whish ak obtect is prpjected towards the player at a velocitb within a normal velocuty range.
Various trciking programx and methods vave been proposed ti enhance the pernormance of athletes, ihcluditg diftary programs, muscular development programs, aerobic conditioning programw, as wxlj as prograjs amd menhobs yor shawpenmnj the mental skilks
agents used as monotherapy. However, combination therapy very at both virus and suppressing a of patients. In US, where combination is widely available, the number of deaths has dramatically declined (Palella, F. J.; Delany, K. M.; Moorman, A. C.; M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. Engl. Med. 338, Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, initial suggest that approximately 30-50% of patients ultimately fail least one drug in suppressive combination. Treatment failure in cases caused by emergence viral Viral resistance in is caused by the replication rate of HIV-1 during the course of infection combined with the relatively viral mutation with the polymerase the of adherence of in taking their prescribed medications. Clearly, need for new antiviral agents, preferably with activity viruses already to currently approved drugs. Other important include improved safety and a more convenient dosing than many of the currently approved drugs. Compounds which inhibit HIV replication have been disclosed. WO2009062285, WO2009062288, WO2009062289, WO2009062308, WO2010130842, WO2011015641, WO2011076765, WO2013123148, WO2014164467, WO2014159959. invention provides advantages, for example, the compounds are novel and are useful in treatment of HIV. Additionally, the compounds provide advantages for pharmaceutical example, regard to one more of their mechanism action, inhibition efficacy, target selectivity, profiles, bioavailability. relates a ocular enhancement training system method for training a player a game in which the player at a velocity within a normal range. Various training programs and methods have proposed to enhance the performance of athletes, including dietary programs, muscular development aerobic conditioning well as programs and methods for sharpening the skills
 agents used as monotherapy. HoWever, combiNatioN thEraPy Has pRoveN very effective AT botH reducing virus and supprEssinG tHE emeRGeNce of ResistaNCe IN A nuMbEr Of pAtIEnTs. In tHe Us, where cOmbination TheRaPy is widely avAIlAble, the numBer Of HIV-related DeaThs has DrAmaTIcallY deClineD (PalelLA, F. J.; DelAny, K. M.; MoorMaN, a. C.; LoveLEss, M. O.; FuRHEr, j.; SatTen, G. A.; Aschman, D. J.; HolMBeRG, S. D. N. Engl. J. Med. 1998, 338, 853-860).
UnFortunAtELy, NOT alL paTients are rEsPonsiVE and a laRGe NUMBer FAil this therapY. In fact, initIAl sTudies SuGgeST that aPproxImATelY 30-50% of patients UltiMately faiL at leaST one druG In the suPpressIve ComBinaTIoN. TReaTmENt fAIlUre IN moSt cases iS cAuSed by The eMERGEnce Of vIral ResisTance. Viral resIstAnce IN tuRn is cAused By thE rEplicAtion rAte of hIv-1 during the coursE of iNfection cOmbInEd wItH the rELativeLy hIgh Viral muTation rATe aSsOCIAtEd with the viral polyMeRASe And the laCk of adHErEnCE of HIV-inFeCteD indIVIdualS in tAKiNg their pRescriBEd MeDicatioNs. clearlY, tHerE is A need FOr neW antivIral agenTs, preFErably with actiVIty against virUSeS ALrEAdy rEsiStant to currEntlY ApprOved DRuGs. OTHer imPortaNt FAcTOrs include improved sAfEty and A more Convenient dosIng regimen THAN many of tHe cuRReNTly approved druGs.
ComPounds whicH Inhibit HiV repLication Have been dISClosed. SeE WO2007131350, wO2009062285, Wo2009062288, WO2009062289, wO2009062308, Wo2010130034, wo2010130842, Wo2011015641, WO2011076765, WO2012033735, WO2013123148, WO2013134113, WO2014164467, anD wo2014159959.
The InVention ProVides teChnIcaL adVanTaGes, for exaMple, the cOmPoUnDs Are Novel ANd are useFuL in ThE trEatmeNT of HIV. additIonaLlY, tHE coMpounds PRoVIDe adVaNtAges For PhArmacEutiCAl uSes, for eXample, witH reGArd tO oNe Or more oF their mechaniSm Of action, biNdIng, InhibiTIOn efficaCy, target selectivity, soluBIlity, saFetY profIles, Or bioavaiLabIlity. THe pREsent iNventiOn relAtEs tO A CondiTIOnEd oCuLar enhanceMENt tRainiNg SystEm and meThod for training a plAYer Of a game in whicH an ObjeCT Is ProJEcTEd tOwARds THE player at a velocIty within a NoRMaL velocity rANge.
vaRious trAining pRograMS and metHods have bEen proposEd To enHANce The performAnce of atHletes, incLUding DIeTary pRogRams, muScUlaR deveLopmenT ProGrams, AerobiC cOnditiOning PrOgrams, as Well as programs and methodS for shArpenIng The mental SkiLLs
 agents used as monotherap y. However , com bin ati on  the rapy  has proven ve r y ef fective at both reduci ng vi ru s  and su ppres sing th e  e m e rge nc eofre s is tance  in  a numb er of pati ent s.  In the US,w he re combina tio n therapy is  wi dely a va ila b le, t henumbe r of H I V-rela ted death sh as dra m aticall y de clin ed (Palella, F. J . ;D elany, K. M.;Moorma n, A. C .;Lov eless, M.O. ; Fur h er, J.; Sa t t e n,G . A.; Aschman , D. J.; Ho l mbe rg, S.  D . N .  Engl.  J. M ed .  19 98, 338, 85 3-86 0).
Unfor tunate l y, nota ll pati ents a reres pons i ve  a ndal arg e  n umb e r f ail this  t he rapy.  Inf a c t , in iti al s tudie s suggest tha t a ppro x ima tely30-50 % of  p atien ts ult imate ly  fail at leastonedrug in t hesu ppr es sivec ombina tio n.Treatme nt fail u rein m o st  cases is caused b yt h eemergenc e of v i ra lr esistanc e.  Vi ralr e sista ncei nturn iscaused by  t he repl ic ationra teofHIV-1 duri ng the  courseof in f ection combine d  with the rel a ti v e ly high  vi ral mutatio n ra t e as soci a te d w i th th e vir al po l ymerase and the lac kof adh erenc e of HIV-infe cted indiv i d u als in t akin g  t h eir prescribed  medi cations. C l early, t hereis a nee d for new a ntiviral  ag ent s,pre f e ra bly with acti v i ty a ga inst vi rus es alre ady  re sis tan tto curren tly appr ov ed  d ru gs.  Othe r  importa nt  fa ct ors  incl u de imp roved  saf et ya nda morec on v e nien tdo sing  re gi men t hanm any  of the  currentl y a p prov ed  d rugs.
C ompounds whic hinhibit HI Vrep licati o n  have be en disclosed. See WO200 7 131350,  WO 20090 6228 5, WO2009 062 288, W O20 0 906228 9, WO2 00906 23 08, W O2010 1 3 00 34,  W O201013084 2 ,  WO 20110 15 641,  WO2011 076765, WO20120337 3 5,WO2013123148,  WO 2013 1 3 41 13, WO 2 014 16 4 467 , and WO201415995 9.
The inv en t io n provides tec hn ical ad vantage s, fo r  exampl e, the co mpounds a re  nov e l  an d are usef ul in th e treatme n t ofH IV . Add iti onally ,the  comp oundsp rov ide a dvanta ge s forpharm ac euticaluses, for example, with  regar d toone  or moreoft hei r mechani sm o f action,bin din g, in hib i tioneffi c ac y,t arget  sel e ctivity,s ol ubi l i ty , safety pr o f i les , orbio a vailab ilit y. The present in v ention relates  toa con dit i oned  o cular enhancem ent  t r a ining sy st em and meth od for t ra i ninga play er ofa gamei n  w h ich an  obj ect  is proje cte dt owardsth ep layerat a  v elocit y with i n an o rmal velocity ra nge.V a rious tra ining  p rograms andmethods ha ve been pro posedto e nhanc e the p er forman ceof  athletes, including  diet ary pro gr ams,  mu scular  dev e l opmen t pr og ram s, aerobi c co n di ti o nin g pr ogram s,  aswell as p r ograms a ndm ethodsfo r s h a rpenin g  t h e  mental sk ill s
 agents_used as_monotherapy. However, combination therapy_has proven_very_effective at_both_reducing virus and_suppressing the emergence_of resistance in a_number of patients._In_the US, where combination therapy is widely available, the number of HIV-related deaths has_dramatically_declined (Palella,_F._J.;_Delany, K. M.; Moorman, A._C.; Loveless, M. O.; Furher,_J.; Satten,_G. A.; Aschman, D. J.; Holmberg, S. D._N._Engl. J. Med._1998, 338, 853-860).
Unfortunately, not all patients are responsive and_a large number fail this therapy._In fact, initial_studies_suggest_that approximately 30-50% of_patients ultimately fail at least one_drug in the suppressive combination. Treatment_failure in most cases is caused by_the emergence of viral resistance. Viral_resistance in turn is caused_by the_replication rate of HIV-1 during_the course of_infection combined_with the relatively_high viral mutation rate associated with_the viral polymerase_and the lack of adherence of_HIV-infected_individuals in taking_their_prescribed_medications. Clearly,_there is a_need_for new_antiviral_agents, preferably with activity against viruses_already_resistant to currently approved drugs. Other important_factors include improved safety_and_a more convenient dosing_regimen than many of the_currently approved drugs.
Compounds which inhibit HIV_replication have_been disclosed._See WO2007131350, WO2009062285, WO2009062288, WO2009062289, WO2009062308, WO2010130034, WO2010130842, WO2011015641, WO2011076765, WO2012033735,_WO2013123148, WO2013134113, WO2014164467, and WO2014159959.
The invention_provides technical advantages, for_example, the_compounds_are novel and_are_useful in_the treatment of HIV. Additionally, the compounds_provide advantages_for pharmaceutical uses, for example, with_regard to one or_more_of their mechanism of action, binding,_inhibition efficacy, target selectivity, solubility, safety_profiles, or bioavailability. The present_invention_relates_to a conditioned ocular enhancement_training system and method for training_a player of_a game in which an object is_projected_towards the player at a velocity_within_a normal velocity range.
Various training programs_and_methods_have been proposed to enhance_the performance of athletes, including dietary_programs, muscular development programs, aerobic conditioning programs, as well_as programs and_methods for sharpening the mental_skills